NCT06308575 2025-01-10
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
M.D. Anderson Cancer Center
Hubei Cancer Hospital
Sun Yat-sen University
The Second Hospital of Hebei Medical University
West China Hospital
Shanxi Province Cancer Hospital